Publications by authors named "Keith Combrink"

Claim this Profile
C
C25-modified rifamycin derivatives with improved activity against .
Laura Paulowski, Katherine S H Beckham, Matt D Johansen, Laura Berneking, Nhi Van, Keith Combrink

PNAS Nexus· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria.
Keith D Combrink, Andrea Ramirez Ramos, Stephanie Spring, Sebastian Schmidl, Kira Elizondo

Bioorg Med Chem Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design and optimization of potent inhibitors of the adenoviral protease.
Philipp Grosche, Finton Sirockin, Aengus Mac Sweeney, Paul Ramage, Paul Erbel, Keith D Combrink

Bioorg Med Chem Lett· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-based optimization of adenain inhibitors.
Aengus Mac Sweeney, Philipp Grosche, David Ellis, Keith Combrink, Paul Erbel

ACS Med Chem Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.
Hwang-Hsing Chen, Abdelmoulah Namil, Bryon Severns, Jennifer Ward, Curtis Kelly, Keith D Combrink

Bioorg Med Chem Lett· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
Paul M Scola, Alan Xiangdong Wang, Andrew C Good, Li-Qiang Sun, Keith D Combrink

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo.
Ny Sin, Brian L Venables, Keith D Combrink, H Belgin Gulgeze, Kuo-Long Yu

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety.
Keith D Combrink, H Belgin Gulgeze, Jan W Thuring, Kuo-Long Yu, Rita L Civiello

Bioorg Med Chem Lett· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity.
Xiangdong Alan Wang, Christopher W Cianci, Kuo-Long Yu, Keith D Combrink, Jan W Thuring

Bioorg Med Chem Lett· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins.
In Ho Kim, Keith D Combrink, Zhenkun Ma, Katrina Chapo, Dalai Yan

Bioorg Med Chem Lett· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.
Kuo-Long Yu, Ny Sin, Rita L Civiello, X Alan Wang, Keith D Combrink

Bioorg Med Chem Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.
Keith D Combrink, Daniel A Denton, Susan Harran, Zhenkun Ma, Katrina Chapo

Bioorg Med Chem Lett· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo.
Kuo-Long Yu, Xiangdong Alan Wang, Rita L Civiello, Ashok K Trehan, Bradley C Pearce, Keith D Combrink

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.
Christopher Cianci, Eugene V Genovesi, Lucinda Lamb, Ivette Medina, Zheng Yang, Keith Combrink

Antimicrob Agents Chemother· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives.
Kuo-Long Yu, Yi Zhang, Rita L Civiello, Ashok K Trehan, Bradley C Pearce, Keith D Combrink

Bioorg Med Chem Lett· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally active fusion inhibitor of respiratory syncytial virus.
Christopher Cianci, Kuo-Long Yu, Keith Combrink, Ny Sin, Bradley Pearce

Antimicrob Agents Chemother· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-HIV antivirals - a review of the recent patent literature.
Keith Combrink

IDrugs· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis